FDA concerned Iterum’s urinary tract infection drug could cause antimicrobial resistance

[cafead]

via Five months after signing off on Utility Therapeutics’ Pivya as the first new treatment for uncomplicated urinary tract infections (uUTIs) in more than two decades, the FDA is weighing the pros and cons of another oral treatment in the indication.

article source